These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2353 related articles for article (PubMed ID: 25838374)

  • 21. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploiting the curative potential of adoptive T-cell therapy for cancer.
    Hinrichs CS; Rosenberg SA
    Immunol Rev; 2014 Jan; 257(1):56-71. PubMed ID: 24329789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is antigen specificity the key to efficient adoptive T-cell therapy?
    Labarriere N; Khammari A; Lang F; Dreno B
    Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive cell transfer therapy.
    Dudley ME; Rosenberg SA
    Semin Oncol; 2007 Dec; 34(6):524-31. PubMed ID: 18083376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive cell therapy: past, present and future.
    Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
    Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy using tumor antigen-reactive T cells.
    Choi BK; Kim SH; Kim YH; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):235-245. PubMed ID: 29370726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive immunotherapy for cancer: harnessing the T cell response.
    Restifo NP; Dudley ME; Rosenberg SA
    Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular Therapy and Cytokine Treatments for Melanoma.
    Borgers JSW; Haanen JBAG
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):129-144. PubMed ID: 33759770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive T-cell therapy of cancer.
    Yee C
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principles of adoptive T cell therapy in cancer.
    Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
    Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
    Ngo MC; Rooney CM; Howard JM; Heslop HE
    Hum Mol Genet; 2011 Apr; 20(R1):R93-9. PubMed ID: 21415041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 118.